PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1803331
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1803331
The global cardiac safety services market is expected to experience robust growth, with its size increasing from USD 811 million in 2024 to USD 2305.1 million by 2032, reflecting a compound annual growth rate (CAGR) of 14.1% from 2025 to 2032. This growth is driven by the growing demand for clinical trial support services that monitor heart health across various stages of drug development. Cardiac safety services are essential for evaluating and ensuring the safety of heart functions during clinical trials, a necessity as the number of drug launches and clinical trials continues to rise globally.
Additionally, increased healthcare spending, advancing medical technologies, and strategic initiatives by leading pharmaceutical companies and research organizations contribute significantly to market expansion. The rising aging population, coupled with the sedentary lifestyle trends among millennials, further accelerates the demand for cardiac safety solutions. The COVID-19 pandemic has also had a positive impact on the market, highlighting the importance of heart health monitoring due to the virus's detrimental effects on the cardiovascular system, further propelling the need for specialized cardiac safety services.
Key Insights
The integrated services category captured the largest share of the market in 2024, holding 80%. These services, which include a comprehensive range of offerings from start to finish of clinical trials, are essential for monitoring heart health during the entire drug development cycle, including imaging solutions and QT studies.
The standalone services segment is expected to grow at the highest rate during the forecast period, driven by the increasing need for specialized, individual services such as blood pressure measurement and ECG monitoring, particularly in late-phase clinical trials.
The ECG/Holter measurement category, holding 65% of the market in 2024, continues to dominate due to its ability to provide continuous, non-invasive monitoring of heart activity. This service is critical in clinical trials, especially for drugs that could affect heart function.
Blood pressure measurement is forecasted to grow at the highest CAGR during the forecast period. With hypertension being a leading risk factor for cardiovascular diseases, its regular monitoring is critical in clinical trials, particularly for drugs related to cardiovascular, nephrology, and metabolic diseases.
AI and machine learning (ML) are revolutionizing the cardiac safety services market. The increasing volume of data generated by wearable and remote monitoring devices demands more efficient and accurate analysis. AI and ML technologies are helping speed up ECG evaluations, reducing costs, and enabling early detection of life-threatening cardiac issues during trials.
Pharmaceutical and biopharmaceutical companies remain the largest market segment, holding 75% of the market in 2024. These companies conduct numerous clinical trials, making cardiac safety services crucial at every stage of drug development, particularly for compounds that may impact heart function.
The contract research organizations (CROs) segment is growing at the highest rate, as more pharmaceutical companies are outsourcing cardiac safety services to CROs. This trend is expected to continue as CROs offer specialized expertise and technology that enhances the accuracy and efficiency of clinical trials.
North America held the largest market share of 40% in 2024, driven by the increasing number of clinical trials and the introduction of innovative cardiac safety products. The high healthcare expenditure and the prevalence of cardiovascular diseases in the region also contribute to the market's growth.
Europe is expected to grow at the highest rate during the forecast period, attributed to the region's strong healthcare infrastructure, aging population, and rising cardiovascular disease rates. European countries are investing heavily in new healthcare technologies, further fueling the demand for cardiac safety services.
In the Asia-Pacific region, China and India are expected to be key contributors to the market's growth, with increasing healthcare investments, a growing aging population, and rising awareness of cardiovascular health.
Leading players in the market include Koninklijke Philips N.V., IQVIA, Medpace Inc., and Eurofins Scientific SE, among others. These companies are continuously innovating, incorporating AI-powered solutions, and expanding their product offerings to stay competitive in the market.
AI-driven innovations such as Philips' Compact Ultrasound 5500CV, which aids in cardiac imaging, and Clario's AI-powered ECG data quality checker, are examples of how technology is enhancing the accuracy and efficiency of cardiac safety services, improving the overall outcomes of clinical trials.
The rising focus on personalized medicine, along with regulatory pressures for more comprehensive cardiac safety assessments, is expected to fuel further demand for these services, creating new opportunities for growth in the cardiac safety services market.